WO2025196686 - FUSED BICYCLIC COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS
National phase entry is expected:
Publication Number
WO/2025/196686
Publication Date
25.09.2025
International Application No.
PCT/IB2025/052930
International Filing Date
20.03.2025
Title **
[English]
FUSED BICYCLIC COMPOUNDS AS SMARCA2 AND/OR SMARCA4 DEGRADERS
[French]
COMPOSÉS BICYCLIQUES FUSIONNÉS UTILISÉS EN TANT QU'AGENTS DE DÉGRADATION DE SMARCA2 ET/OU DE SMARCA4
Applicants **
AURIGENE ONCOLOGY LIMITED
Inventors
ABBINENI, Chandrasekhar
SAMAJDAR, Susanta
KUILA, Bilash
Priority Data
202441021032
20.03.2024
IN
202441071928
24.09.2024
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4539 | |
| EPO | Filing, Examination, Granting | 30495 | |
| Japan | Filing, Examination, Granting | 3177 | |
| South Korea | Filing, Examination, Granting | 4037 | |
| USA | Filing, Examination, Granting | 14490 |
Total:
56,738
Contact Us
Abstract[English]
The present invention provides fused bicyclic compounds of formula (I), which are therapeutically useful as SMARCA2 and/or SMARCA4 degraders. These compounds are useful in the treatment and/or delaying progression of disease or disorder dependent upon SMARCA2 and/or SMARCA4 in a subject. The present invention also provides pharmaceutical compositions comprising at least one of the compounds of formula (I) or a pharmaceutically acceptable salt or a stereoisomer or a tautomer thereof.[French]
La présente invention concerne des composés bicycliques fusionnés de formule (I), qui sont thérapeutiquement utiles en tant qu'agents de dégradation de SMARCA2 et/ou de SMARCA4. Ces composés sont utiles dans le traitement et/ou le retardement de la progression d'une maladie ou d'un trouble dépendant de SMARCA2 et/ou de SMARCA4 chez un sujet. La présente invention concerne également des compositions pharmaceutiques comprenant au moins l'un des composés de formule (I) ou un sel pharmaceutiquement acceptable ou un stéréoisomère ou un tautomère de ceux-ci.